ArticleMayo Clinic proceedings. Innovations, quality & outcomes2021
Efficacy of
Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Rational Radionuclide Therapy for Recurrent Meningioma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Diarylpentanoid, a curcumin analog, inhibits malignant meningioma growth in bothWorld journal of experimental medicine · 2025Article
- Review
- A high content clonogenic survival drug screening identifies maytansine as a potent radiosensitizer for meningiomas.Frontiers in immunology · 2025Article
- The Evolving Classification of Meningiomas: Integration of Molecular Discoveries to Inform Patient Care.Cancers · 2024Review
- Establishing a robust radioligand therapy program: A practical approach for North American centers.Cancer medicine · 2024Review
- A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.Radiology. Imaging cancer · 2023Review
- Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review.Neurologia medico-chirurgica · 2022Review
- Challenges and future options for the production of lutetium-177.European journal of nuclear medicine and molecular imaging · 2021Article
- A fluorescein-conjugated somatostatin receptor antagonist adapter for chimeric antigen receptor T cell therapy of meningioma.Neuro-oncology advancesArticle
- Assessment ofJournal of medical physicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A 62-year-old man presented with a history of atypical meningioma (World Health Organization grade II) and recurrent as anaplastic meningioma (World Health Organization grade III). His previous treatments included multiple surgical resections, fractionated radiation therapy, stereotactic radiosurgery, everolimus/octreotide long-acting release, bevacizumab, and hydroxyurea. Magnetic resonance imaging revealed rapid volumetric progression over the prior 9 months, with a near tripling in size from 29.9 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.